Indeed, clinical trials with FGF-21 analog monotherapy (e.g., pegbelfermin, efruxifermin, and BOS-580) have generated favorable results in NAFLD, as elsewhere summarized [52]. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.